Amylyx Pharmaceuticals, Inc. (AMLX)
NASDAQ: AMLX · Real-Time Price · USD
3.560
-0.100 (-2.73%)
Mar 31, 2025, 1:17 PM EDT - Market open

Company Description

Amylyx Pharmaceuticals, Inc a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States.

Its lead products candidate includes avexitide, an investigational, first-in-class glucagon-like peptide-1, or GLP-1 receptor antagonist, which is in phase 3 clinical trial to treat post-bariatric hypoglycemia and congenital hyperinsulinism.

The company also develops AMX0035, an oral, fixed-dose combination of sodium phenylbutyrate and taurursodiol which is phase 2 clinical trial for the treatment of wolfram syndrome, as well as in phase 2b/3 clinical trial to treat progressive supranuclear palsy; AMX0114, which is in phase 1 clinical trial for the treatment of amyotrophic lateral sclerosis; and long-acting GLP-1 receptor antagonist to treat post-bariatric hypoglycemia and other rare diseases.

Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Amylyx Pharmaceuticals, Inc.
Amylyx Pharmaceuticals logo
Country United States
Founded 2014
IPO Date Jan 7, 2022
Industry Biotechnology
Sector Healthcare
Employees 123
CEO Joshua B. Cohen

Contact Details

Address:
43 Thorndike Street
Cambridge, Massachusetts 02141
United States
Phone 617 682 0917
Website amylyx.com

Stock Details

Ticker Symbol AMLX
Exchange NASDAQ
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
IPO Price $19.00
CIK Code 0001658551
CUSIP Number 03237H101
ISIN Number US03237H1014
Employer ID 46-4600503
SIC Code 2834

Key Executives

Name Position
Justin B. Klee Co-Founder, Co-Chief Executive Officer and Director
Joshua B. Cohen Co-Founder, Co-Chief Executive Officer and Director
James M. Frates M.B.A. Chief Financial Officer
Gina M. Mazzariello J.D. Chief Legal Officer and General Counsel
Dr. Camille L. Bedrosian M.D. Chief Medical Officer
Tom Holmes Chief Technical Operations Officer
Lindsey Allen Head of Investor Relations and Communications
Linda A. Arsenault Chief Human Resources Officer
Tammy Sarnelli Global Head of Regulatory Affairs
Dr. Machelle Manuel Ph.D. Vice President and Head of Global Medical Affairs

Latest SEC Filings

Date Type Title
Mar 26, 2025 EFFECT Notice of Effectiveness
Mar 4, 2025 S-8 Securities to be offered to employees in employee benefit plans
Mar 4, 2025 S-3 Registration statement under Securities Act of 1933
Mar 4, 2025 10-K Annual Report
Mar 4, 2025 POSASR Filing
Mar 4, 2025 8-K Current Report
Feb 14, 2025 SCHEDULE 13G/A Filing
Feb 14, 2025 SCHEDULE 13G/A Filing
Jan 14, 2025 SCHEDULE 13G Filing
Jan 10, 2025 8-K Current Report